Kymera Therapeutics (NASDAQ:KYMR) COO Sells $349,080.82 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 4,279 shares of the company’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $81.58, for a total transaction of $349,080.82. Following the transaction, the chief operating officer owned 44,018 shares of the company’s stock, valued at $3,590,988.44. This represents a 8.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded up $0.93 during trading on Wednesday, hitting $81.70. 330,315 shares of the stock were exchanged, compared to its average volume of 667,424. The stock’s fifty day moving average is $83.24 and its 200 day moving average is $78.99. The stock has a market cap of $6.72 billion, a PE ratio of -22.89 and a beta of 2.06. Kymera Therapeutics, Inc. has a 12 month low of $28.33 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.82) earnings per share. Sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Several large investors have recently made changes to their positions in the business. Baker BROS. Advisors LP grew its stake in shares of Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after purchasing an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Kymera Therapeutics by 9.4% in the 4th quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after purchasing an additional 190,383 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on KYMR. UBS Group upped their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Barclays upped their price target on shares of Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 27th. Piper Sandler upped their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Citigroup upped their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $118.10.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.